Circulating tumour DNA analysis to direct therapy in advanced breast cancer
 

I have been waiting for significant data on this subject (“liquid biopsy”) for 2 decades now. Even with many tumor sites, it’s always risky to get my wife biopsy. Due to tumor heterogeneity one can only hope the biopsy sample represents the biology of the majority of tumor. With CTC, my lay person thinking is that CTCs represent the majority and particularly the more dangerous type that likely settle to other parts of the body. So here we are, fresh off the ongoing ESSO conference.

https://www.thelancet.com/journals/l...444-7/fulltext

Nguyen